NCT00144664已完成3 期
An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 19
- 主要终点
- Efficacy:Percentage of patients showing 30% improvement in the JIA core set on LOBS
研究概览
简要总结
This is an open-label, Phase III study to evaluate the efficacy, safety and PK of MRA in patients with pJIA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 19 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
MRA(Tocilizumab)
干预措施: MRA(Tocilizumab) (Drug)
结局指标
主要结局
Efficacy:Percentage of patients showing 30% improvement in the JIA core set on LOBS
时间窗: whole period
Safety:Incidence and severity of adverse events and adverse drug reactions
时间窗: whole period
Pharmacokinetics:The Cmax, trough values, AUC, Kel, CL, Vd, Vdss, and t1/2 for serum MRA concentration
时间窗: whole period
次要结局
- Efficacy:The time course of the percentage of patients showing 30%, 50%, and 70% improvement in the JIA core set, each evaluation endpoint in the JIA core set, CRP, pain up to LOBS(whole period)
研究者
相似试验
已完成
3 期
PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)Rheumatoid ArthritisNCT00380601Chugai Pharmaceutical20
已完成
3 期
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)Systemic Juvenile Idiopathic ArthritisNCT00144599Chugai Pharmaceutical56
已完成
3 期
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)Rheumatoid ArthritisNCT00144508Chugai Pharmaceutical306
已完成
3 期
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)Systemic Juvenile Idiopathic ArthritisNCT00144612Chugai Pharmaceutical60
已完成
不适用
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal ImpairmentRheumatoid ArthritisNCT00144573Chugai Pharmaceutical14